These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 23648144)
21. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304 [TBL] [Abstract][Full Text] [Related]
22. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related]
23. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957 [TBL] [Abstract][Full Text] [Related]
24. Mechanistic Target of Rapamycin Is a Novel Molecular Mechanism Linking Folate Availability and Cell Function. Silva E; Rosario FJ; Powell TL; Jansson T J Nutr; 2017 Jul; 147(7):1237-1242. PubMed ID: 28592519 [TBL] [Abstract][Full Text] [Related]
25. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727 [TBL] [Abstract][Full Text] [Related]
26. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity. Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526 [TBL] [Abstract][Full Text] [Related]
27. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Copp J; Manning G; Hunter T Cancer Res; 2009 Mar; 69(5):1821-7. PubMed ID: 19244117 [TBL] [Abstract][Full Text] [Related]
28. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840 [TBL] [Abstract][Full Text] [Related]
29. Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells. Wang CX; Torbett BE Curr Opin Hematol; 2015 Jul; 22(4):302-8. PubMed ID: 26049750 [TBL] [Abstract][Full Text] [Related]
30. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Gan B; Hu J; Jiang S; Liu Y; Sahin E; Zhuang L; Fletcher-Sananikone E; Colla S; Wang YA; Chin L; Depinho RA Nature; 2010 Dec; 468(7324):701-4. PubMed ID: 21124456 [TBL] [Abstract][Full Text] [Related]
31. Hypothalamic mTOR: the rookie energy sensor. Martínez de Morentin PB; Martinez-Sanchez N; Roa J; Ferno J; Nogueiras R; Tena-Sempere M; Dieguez C; Lopez M Curr Mol Med; 2014 Jan; 14(1):3-21. PubMed ID: 24236459 [TBL] [Abstract][Full Text] [Related]
32. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075 [TBL] [Abstract][Full Text] [Related]
33. Mechanistic target of rapamycin: integrating growth factor and nutrient signaling in the collecting duct. Brown AL; Fluitt MB; Ecelbarger CM Am J Physiol Renal Physiol; 2018 Sep; 315(3):F413-F416. PubMed ID: 29846113 [TBL] [Abstract][Full Text] [Related]
34. Adaptive responses to Fan C; Zhao C; Zhang F; Kesarwani M; Tu Z; Cai X; Davis AK; Xu L; Hochstetler CL; Chen X; Guo F; Huang G; Azam M; Tian W; Lu QR; Zheng Y Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443202 [TBL] [Abstract][Full Text] [Related]
35. Dynamic modeling of signal transduction by mTOR complexes in cancer. Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485 [TBL] [Abstract][Full Text] [Related]
36. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Kaur A; Sharma S Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246 [TBL] [Abstract][Full Text] [Related]
37. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308 [TBL] [Abstract][Full Text] [Related]
38. Mammalian target of rapamycin and the kidney. I. The signaling pathway. Lieberthal W; Levine JS Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691 [TBL] [Abstract][Full Text] [Related]
39. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia. Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307 [TBL] [Abstract][Full Text] [Related]
40. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition. Matsubara S; Tsukasa K; Kuwahata T; Takao S Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]